1. 筒井裕之, 磯部光章, 伊藤宏, 伊藤浩, 奥村謙, 小野稔, 北風政史, 絹川弘一郎, 木原康樹, 後藤葉一, 小室一成, 齋木佳克, 斎藤能彦, 坂田泰史, 佐藤直樹, 澤芳樹, 塩瀬明, 清水渉, 下川宏明, 清野精彦, 野出孝一, 肥後太基, 平山篤志, 眞茅みゆき, 増山理, 室原豊明, 百村伸一, 矢野雅文, 山崎健二, 山本一博, 吉川勉, 吉村道博. 急性・慢性心不全診療ガイドライン(2017 年改訂版). 日本循環器学会/日本心不全学会. 2017.
2. Yasuda S, Miyamoto Y and Ogawa H. Current Status of Cardiovascular Medicine in the Aging Society of Japan. Circulation. 2018;138:965-967.
3. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K and Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1:4-25.
4. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM and Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175:996-1004.
5. Leyva F, Chua T, Anker S and Coats A. Uric acid in chronic heart failure : a measure of the anaerobic threshold. Metabolism. 1998;47:1156-59.
6. Leyva F, Anker S, Godsland I, Teixeira M, Hellewell P, Kox W, Poole-Wlson P and Coats A. Uric acid in chronic heart failure : a marker of chronic inflammation. Eur Heart J. 1998;19:1814-22.
7. 久米一郎, 市田公美, 嶺尾郁夫, 安西尚彦, 上田孝典, 鎌谷直之, 登勉, 細谷龍男, 細山田真, 森崎隆幸, 山田裕一, 山中寿. 高尿酸血症・痛風の治療ガイドライン第 3 版. 日本痛風・核酸代謝学会. 2019:1-169.
8. Choi HK and Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442-7.
9. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez- Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F and Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases. 2017;76:29-42.
10. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS and Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72:744-760.
11. Kaufman M and Guglin M. Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev. 2013;18:177-86.
12. Sorensen L and Levinson D. Origin and extrarenal elimination of uric acid in man. Nephron. 1975;14:7-20.
13. Berry CE and Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555:589-606.
14. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P and Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-7.
15. J Xiao, S-B D, Q She, J Li, G-Y Kao, J-S Wang and Ma Y. Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2016;20:756-61.
16. Hare JM, Mangal B, Brown J, Fisher C, Jr., Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP and Investigators O-C. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51:2301-9.
17. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF and Network NHFCR. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015;131:1763-71.
18. Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y and Ogawa H. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019;40:1778- 1786.
19. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L and Investigators C. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378:1200- 1210.
20. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD and Doehner W. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3:73-81.
21. Sautin YY and Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27:608-19.
22. 四ノ宮成祥, 市田公美, 太田原顕, 荻野和秀, 中山昌喜, 箱田雅之, 浜田紀宏, 久留一郎, 細山田真, 松尾洋孝 and 山口聡. 腎性低尿酸血症診療ガイドライン. 厚生労働科学研究費補助金（難治性疾患政策研究事業）： 腎・泌尿器系の希少・難治性疾患群に関する診断基準・ 診療ガイドラインの確立研究班（腎性低尿酸血症担当）日本痛風・核酸代謝学会. 2017.
23. Ohta T, Sakano T, Igarashi T, Itami N, Ogawa T and Group ARFAwRHR. Exercise-induced acute renal failure associated with renal hypouricaemia: results of a questionnaire-based survey in Japan. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2004;19:1447-53.
24. Wakasugi M, Kazama JJ, Narita I, Konta T, Fujimoto S, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Asahi K, Kimura K, Kondo M, Kurahashi I, Ohashi Y and Watanabe T. Association between hypouricemia and reduced kidney function: a cross-sectional population-based study in Japan. American journal of nephrology. 2015;41:138-46.
25. Wu AH, Gladden JD, Ahmed M, Ahmed A and Filippatos G. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4-7.
26. Cho SK, Chang Y, Kim I and Ryu S. U-Shaped Association Between Serum Uric Acid Level and Risk of Mortality: A Cohort Study. Arthritis Rheumatol. 2018;70:1122-1132.
27. Tseng WC, Chen YT, Ou SM, Shih CJ, Tarng DC and Taiwan Geriatric Kidney Disease Research G. U-Shaped Association Between Serum Uric Acid Levels With Cardiovascular and All-Cause Mortality in the Elderly: The Role of Malnourishment. J Am Heart Assoc. 2018;7.
28. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C and Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36:1072-8.
29. Mazza A, Zamboni S, Rizzato E, Pessina AC, Tikhonoff V, Schiavon L and Casiglia E. Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin- dependent diabetic elderly people. The CArdiovascular STudy in the ELderly (CASTEL). Acta Diabetol. 2007;44:99-105.
30. Hsu SP. Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrology Dialysis Transplantation. 2004;19:457-462.
31. Culleton BF, Larson MG, Kannel WB and Levy D. Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study. Ann Intern Med. 1999;131:7-13.
32. Feig DI, Kang DH and Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-21.
33. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF and Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62:170-80.
34. Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD and Ahmed A. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J. 2011;32:712-20.
35. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A and Tsutsui H. Hyperuricemia predicts adverse outcomes in patients with heart failure. International Journal of Cardiology. 2011;151:143-147.
36. Mantovani A, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP and Investigators G-H. Prognostic impact of elevated serum uric acid levels on long- term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. Metabolism. 2018;83:205-215.
37. Tamariz L, Harzand A, Palacio A, Verma S, Jones J and Hare J. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17:25-30.
38. Duan X and Ling F. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses. 2008;70:578-81.
39. Shiba N, Nochioka K, Miura M, Kohno H and Shimokawa H. Trend of Westernization of Etiology and Clinical Characteristics of Heart Failure Patients in Japan. Circulation Journal. 2011;75:823-833.
40. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H and Investigators C-. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017;19:1258-1269.
41. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Takahashi J, Shimokawa H and Investigators C-. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan -- report from the CHART Studies. Circ J. 2015;79:2396-407.
42. Miura M, Sugimura K, Sakata Y, Miyata S, Tadaki S, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H and Investigators C-. Prognostic Impact of Loop Diuretics in Patients With Chronic Heart Failure- Effects of Addition of Renin-Angiotensin-Aldosterone System Inhibitors and beta-Blockers. Circ J. 2016;80:1396-403.
43. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Shimokawa H and Investigators C-. Prognostic Impact of Diabetes Mellitus in Chronic Heart Failure According to Presence of Ischemic Heart Disease - With Special Reference to Nephropathy. Circ J. 2015;79:1764-72.
44. Hunt SA, American College of C and American Heart Association Task Force on Practice G. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1-82.
45. McKee PA, Castelli WP, McNamara PM and Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-6.
46. Breiman L, Friedman J, Olshen R and Stone C. Classification and Regression Trees, Wadsworth, Belmont, California; 1984.
47. Bou-Hamad. I, Larocque. D and Ben-Ameur H. A review of survival trees. Stat Surv. 2011;5:44-71.
48. Dobson A. Is raised serum uric acid a cause of cardiovascular disease or death? The Lancet. 1999;354.
49. Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, Zhang Z and Yang Z. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. J Clin Endocrinol Metab. 2015;100:4198-207.
50. Zhu P, Liu Y, Han L, Xu G and Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One. 2014;9:e100801.
51. Li M, Hu X, Fan Y, Li K, Zhang X, Hou W and Tang Z. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose- response meta-analysis. Sci Rep. 2016;6:19520.
52. Pascual E and Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis. 2006;65:981-2.
53. Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, Jing X, Chen J and Wang J. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16:15-24.
54. Maesaka JK and Fishbane S. Regulation of renal urate excretion: A critical review. American Journal of Kidney Diseases. 1998;32:917-933.
55. Bandaru P and Shankar A. Association between Serum Uric Acid Levels and Diabetes Mellitus. Int J Endocrinol. 2011;2011:604715.
56. Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P and King H. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol. 1988;127:321-36.
57. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y and H E. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447-52.
58. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, Wiriyasermkul P, Kikuchi Y, Oda T, Nishiyama J, Nakamura T, Morimoto Y, Kamakura K, Sakurai Y, Nonoyama S, Kanai Y and Shinomiya N. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008;83:744-51.
59. Stubnova V, Os I, Hoieggen A, Solbu MD, Grundtvig M, Westheim AS, Atar D and Waldum-Grevbo B. Gender differences in association between uric acid and all- cause mortality in patients with chronic heart failure. BMC Cardiovasc Disord. 2019;19:4.
60. Alimonda AL, Nunez J, Nunez E, Husser O, Sanchis J, Bodi V, Minana G, Robles R, Mainar L, Merlos P, Darmofal H and Llacer A. Hyperuricemia in acute heart failure. More than a simple spectator? Eur J Intern Med. 2009;20:74-9.
61. Choe JY, Park SH, Kim JY, Shin IH and Kim SK. Change in serum uric acid between baseline and 1-year follow-up and its associated factors in male subjects. Clin Rheumatol. 2008;27:483-9.
62. Nochioka K, Shiba N, Kohno H, Miura M and Shimokawa H. Both high and low body mass indexes are prognostic risks in Japanese patients with chronic heart failure: implications from the CHART study. J Card Fail. 2010;16:880-7.
63. Maxwell S, Thomason H, Sandler D, Leguen C, Baxter M, Thorpe G, Jones A and Barnett A. Antioxidant status in patients with uncomplicatedinsulin-dependent and non-insulin-dependentdiabetes mellitus. Eur J Clin Invest. 1997;27:484-90.
64. Ames B, Cathcart R, Schwiers E and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858-62.
65. De Becker B, Coremans C, Chaumont M, Delporte C, Van Antwerpen P, Franck T, Rousseau A, Zouaoui Boudjeltia K, Cullus P and van de Borne P. Severe Hypouricemia Impairs Endothelium-Dependent Vasodilatation and Reduces Blood Pressure in Healthy Young Men: A Randomized, Placebo-Controlled, and Crossover Study. J Am Heart Assoc. 2019;8:e013130.
66. Sugihara S, Hisatome I, Kuwabara M, Niwa K, Maharani N, Kato M, Ogino K, Hamada T, Ninomiya H, Higashi Y, Ichida K and Yamamoto K. Depletion of Uric Acid Due to SLC22A12 (URAT1) Loss-of-Function Mutation Causes Endothelial Dysfunction in Hypouricemia. Circ J. 2015;79:1125-32.
67. Sena CM, Leandro A, Azul L, Seiça R and Perry G. Vascular Oxidative Stress: Impact and Therapeutic Approaches. Frontiers in physiology. 2018;9:1668.
68. Alvarez-Lario B and MacArron-Vicente J. Is there anything good in uric acid? Qjm. 2011;104:1015-1024.
69. Antón FM, García Puig J, Ramos T, González P and Ordás J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35:343-8.
70. Saghafi-Asl M and Vaghef-Mehrabany E. Comprehensive comparison of malnutrition and its associated factors between nursing home and community dwelling elderly: A case-control study from Northwestern Iran. Clin Nutr ESPEN. 2017;21:51-58.
71. Xue L, Liu Y, Xue H, Xue J, Sun K, Wu L and Hou P. Low uric acid is a risk factor in mild cognitive impairment. Neuropsychiatr Dis Treat. 2017;13:2363-2367.
72. Black CN, Bot M, Scheffer PG, Snieder H and Penninx B. Uric acid in major depressive and anxiety disorders. Journal of affective disorders. 2018;225:684-690.
73. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, Shimokawa H and Investigators C-. Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study. Eur J Heart Fail. 2012;14:367-76.
74. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J and Shimokawa H. Prognostic Impact of Subclinical Microalbuminuria in Patients With Chronic Heart Failure. Circulation Journal. 2014;78:2890-2898.
75. Holme I, Aastveit AH, Hammar N, Jungner I and Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009;266:558-70.
論文の公開元へ
